Skip to main content

Table 3 Clinical features of COVID-19 in our patient cohort

From: COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  n %
COVID-19 infection
Asymptomatic 675 17.8
Mild 658 17.3
Severe 1736 45.7
Critical 689 18.1
Unknown 43 1.1
COVID-19 test samplea
BAL 60 1.6
SARS-CoV-2 nasopharyngeal swab 3700 97.3
SARS-CoV-2 serology 86 2.3
Reason for COVID-19 testa
Pulmonary symptoms 1454 38.3
Pulmonary + extrapulmonary symptoms 831 21.9
Extrapulmonary symptoms 742 19.5
Screening 727 19.1
Unknown 47 1.2
Neutrophils level at COVID-19 diagnosisb
≤ 0.5 × 109/mm3 280 7.4
0.501–0.999 × 109/mm3 217 5.7
 ≥ 1 × 109/mm3 2738 72.0
Lymphocytes level at COVID-19 diagnosisb
 ≤  0.2 × 109/mm3 344 9.1
0.201–0.499 × 109/mm3 538 14.2
 ≥ 0.5 × 109/mm3 2367 62.3
Stay during COVID-19
Admitted to hospital 2778 73.1
Length of hospital stay, median (IQR) [range] 15 (8–27), [1–235]
ICU 689 18.1
Length of ICU stay, median (IQR) [range] 11 (5–20), [1–111]
 Invasive MV 449 11.8
 Non-invasive MV 221 5.8
Clinical outcome of COVID-19
Death 1185 31.2
Observation time, median (IQR) [range] 89 (21–172), [0–436]
Reason for deatha
Not related to COVID-19 125 3.3
Contributable by COVID-19 155 4.1
Attributable to COVID-19 843 22.2
Attributable to HM 328 8.6
Death due to other reasons 123 3.2
Death due to unknown reasons 78 2.1
  1. BAL Bronchoalveolar lavage, COVID-19 coronavirus disease 19, HM hematological malignancy, ICU intensive care unit, MV mechanical ventilation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  2. aData can be super additive
  3. bData not available in all patients